Transfusion medicine

EQS-News: EVOMEDIS Announces Strategic Partnership with Medical University of Graz and COREMED Graz to Foster Wound Healing Innovation

Retrieved on: 
Thursday, December 7, 2023
Burns, Medical school, Regenerative medicine, Orphan, Atakent (business cooperation center), Partnership, European Medicines Agency, Transfusion medicine, ATMP, RESEARCH, Serology, Wound healing, GMP, Pharmaceutical industry, Nursing, Austria, Germany

Investing in the future of burn medicine: Alliance to develop new cell-based therapy

Key Points: 
  • Investing in the future of burn medicine: Alliance to develop new cell-based therapy
    Graz, Austria, 23 November 2023 – EVOMEDIS GmbH (EVOMEDIS), an R&D stage life science company developing next-generation wound healing solutions, today announced the initiation of a strategic partnership with the Medical University of Graz (MedUni) and COREMED (Cooperative Center for Regenerative Medicine / JOANNEUM RESEARCH Forschungsgesellschaft mbH) to propel the shift from wound care to wound healing through innovative solutions.
  • EVOMEDIS has pledged an investment of €1.5 million over a span of two years for a collaborative project.
  • We have set up our operations at MedUni, which is part of the Medical Science City Graz (MSCG).
  • This perfectly aligns with our strategy of working closely with local partners to develop new innovations for wound healing up to clinical proof-of-concept.

Cerus Corporation Announces Third Quarter 2023 Financial Results

Retrieved on: 
Thursday, November 2, 2023
Medical Supplies, Health, Hospitals, Health Technology, Other Health, General Health, Biotechnology, CERS, Government, Red blood cell, SG, EBITDA, Research, R, Growth, Corporation, Transfusion medicine, Investment, Patient, Cryptocurrency, Video game, Pharmaceutical industry, Renting, Bookkeeping, Canadian Blood Services, Cerus Corporation

Cerus Corporation (Nasdaq: CERS) today announced financial results for the third quarter ended September 30, 2023.

Key Points: 
  • Cerus Corporation (Nasdaq: CERS) today announced financial results for the third quarter ended September 30, 2023.
  • Product gross margin for the third quarter of 2023 was 54.9% compared to 55.4% for the third quarter of 2022.
  • R&D expenses for the third quarter of 2023 were $16.8 million, compared to $16.2 million for the third quarter of 2022.
  • Net loss attributable to Cerus Corporation for the third quarter of 2023 was $7.3 million, or $0.04 per basic and diluted share, compared to a net loss attributable to Cerus Corporation of $8.5 million, or $0.05 per basic and diluted share, for the third quarter of 2022.

QuidelOrtho Reports Third Quarter 2023 Financial Results

Retrieved on: 
Wednesday, November 1, 2023
Data Management, Medical Supplies, Health, Technology, Health Technology, General Health, Transfusion medicine, Sanfilippo syndrome, EBITDA, QuidelOrtho, EPS, GAAP, COVID-19, Patient, Virus, Pharmaceutical industry

QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced financial results for the third quarter ended October 1, 2023.

Key Points: 
  • QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced financial results for the third quarter ended October 1, 2023.
  • Foreign currency translation did not significantly impact third quarter 2023 results.
  • GAAP diluted loss per share for the third quarter of 2023 was $(0.19), compared to diluted EPS of $0.28 for the third quarter of 2022.
  • The Company is maintaining its 2023 financial guidance, provided on August 8, 2023, as follows:

QuidelOrtho Reports Preliminary Revenue Results for the Third Quarter 2023

Retrieved on: 
Thursday, October 12, 2023
Research, General Health, Pharmaceutical, Data Management, Technology, Infectious Diseases, Clinical Trials, Science, COVID-19, Biotechnology, Other Science, Health, Transfusion medicine, SARS, QuidelOrtho, Pharmaceutical industry

QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced strong preliminary unaudited revenue results for the fiscal third quarter ended October 1, 2023, primarily driven by higher respiratory product sales, particularly SARS and flu.

Key Points: 
  • QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced strong preliminary unaudited revenue results for the fiscal third quarter ended October 1, 2023, primarily driven by higher respiratory product sales, particularly SARS and flu.
  • Total revenues of $738 million to $744 million;
    Non-respiratory product revenue of $557 million to $560 million; and
    Respiratory product revenue of $181 million to $184 million.
  • “Our strong performance in the third quarter reflects the critical role our technologies play in healthcare settings and the trust medical professionals place in us,” said Douglas Bryant, President and Chief Executive Officer, QuidelOrtho.
  • The Company is maintaining its 2023 financial guidance, provided on August 8, 2023, as follows:

Cerus Corporation Announces Workshop and Abstracts at the 2023 AABB Annual Meeting

Retrieved on: 
Tuesday, October 10, 2023
General Health, Health, Other Health, CDT, American Red Cross, Central Time Zone, Abstract, University of Texas Southwestern Medical Center, UCSF Medical Center, Transfusion medicine, University, Stanford University, Corporation, CERS, Use, Pharmaceutical industry, Vaccine, Cerus Corporation

Cerus Corporation (Nasdaq:CERS) today announced a selection of abstracts and an industry workshop at the 2023 AABB Annual Meeting, taking place in Nashville, TN from October 14 through October 17.

Key Points: 
  • Cerus Corporation (Nasdaq:CERS) today announced a selection of abstracts and an industry workshop at the 2023 AABB Annual Meeting, taking place in Nashville, TN from October 14 through October 17.
  • This year’s AABB Annual Meeting attracts individuals and institutions from around the globe involved in the fields of transfusion medicine and biotherapies.
  • The following is a select list of presentations and abstracts of interest for Cerus.
  • Sunday, October 15, 2023 – 10:00 a.m.– Pathogen Reduced Cryoprecipitate: Early Experiences and Inventory Management Outcomes (Chair: M.S.

QuidelOrtho Receives CLIA Waiver for Sofia® 2 SARS Antigen+ FIA

Retrieved on: 
Thursday, September 21, 2023
FDA, Health, Infectious Diseases, COVID-19, Pharmaceutical, Biotechnology, De novo, FIA, Transfusion medicine, SARS-CoV-2, SARS, QuidelOrtho, Coinfection, CLIA, Risk, WALK, READ, Genetically modified bacteria, Peter Hancock (professor), Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Virus, Food, Disease, Vaccine

QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that it has been granted CLIA Waiver from the U.S. Food and Drug Administration (FDA), applying to its new Sofia® 2 SARS Antigen+ FIA.

Key Points: 
  • QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that it has been granted CLIA Waiver from the U.S. Food and Drug Administration (FDA), applying to its new Sofia® 2 SARS Antigen+ FIA.
  • The Sofia 2 SARS Antigen+ FIA is the first rapid antigen test that detects COVID-19 to be awarded FDA market clearance through the FDA’s De Novo process and is now the first rapid antigen test also to receive CLIA waiver.
  • With the CLIA waiver, the Sofia 2 SARS Antigen+ FIA is deemed to be so simple and at such low risk of error that it no longer requires administration by trained clinical laboratory personnel, opening broader use in virtually any point-of-care setting equipped with Sofia 2 instruments.
  • “As the first company to introduce a rapid antigen test for COVID-19 when the FDA granted Emergency Use Authorization for the Sofia SARS Antigen FIA in May of 2020, and the first to receive De Novo FDA clearance for our Sofia 2 SARS Antigen+ FIA, it is gratifying to also be the first to receive a full CLIA waiver for our Sofia 2 SARS Antigen+ FIA,” said Douglas Bryant, President and Chief Executive Officer of QuidelOrtho.

Trinity Life Sciences Appoints Advisory Board

Retrieved on: 
Wednesday, September 20, 2023
Software, Other Health, General Health, Pharmaceutical, Data Management, Technology, Artificial Intelligence, Health Technology, Science, Biotechnology, Other Technology, Health, Other Science, Amgen, GSK plc, Nursing care plan, Accenture, IQVIA, Trinity, Baxter, Market access, Innovation, Ortho Clinical Diagnostics, Bristol Myers Squibb, Central Waqf Council, WW, Neptune Wellness Solutions, Transfusion medicine, Johnson & Johnson, BMS, Digital, Social media, Financial adviser, Management, Pharmaceutical industry, Pharma, Automotive industry

Trinity Life Sciences , a leader in global life sciences commercialization solutions, has announced its Board of Advisors, a group of independent, expert advisors that will help advance Trinity’s mission .

Key Points: 
  • Trinity Life Sciences , a leader in global life sciences commercialization solutions, has announced its Board of Advisors, a group of independent, expert advisors that will help advance Trinity’s mission .
  • Trinity is the fourth company Mr. Corcoran has founded or co-founded, after successful endeavors in social media, medical devices, and pharma- and biotech-focused software development.
  • “My team and I are thrilled to be working with the foremost innovative thinkers in our industry,” said Leslie Orne , President & CEO of Trinity Life Sciences.
  • “Their combined expertise is second to none and will serve as guiding voices as Trinity continues to transform the way life sciences companies think about and execute on their goals.”

Fresenius Kabi and AABB Announce Start of 18th Annual Blood Collectors Week September 3-9, 2023

Retrieved on: 
Sunday, September 3, 2023
General Health, Other Health, Health, Pharmaceutical, Medical Supplies, Partnership, CAE, Fresenius (company), Life, AABB, Transfusion medicine, Multimedia, Kabi, Patient, Blood, World Blood Donor Day, Social media, Safety, Medical device

Fresenius Kabi and AABB proudly announce the dates of the 18th annual Blood Collectors Week , which runs September 3-9, 2023.

Key Points: 
  • Fresenius Kabi and AABB proudly announce the dates of the 18th annual Blood Collectors Week , which runs September 3-9, 2023.
  • "We are delighted to partner with AABB once again to celebrate Blood Collectors Week and honor the unwavering dedication of blood collectors in the U.S.," said Dean Gregory, president, MedTech Global Commercial Operations at Fresenius Kabi.
  • “Our nation’s blood collectors are dedicated professionals who work tirelessly every day to ensure the safety and availability of the blood supply.
  • To learn more about blood donation, find a local blood collection site, or download resources for your Blood Collectors Week celebration, visit www.bloodcollectors.org .

QuidelOrtho to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference

Retrieved on: 
Monday, August 28, 2023
Technology, Biotechnology, Health, Data Management, Morgan Stanley, Morgan, Conference, Transfusion medicine, Medical device, Management

QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that members of its management team are scheduled to participate in the Morgan Stanley 21st Annual Global Healthcare Conference in New York on September 12, 2023.

Key Points: 
  • QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that members of its management team are scheduled to participate in the Morgan Stanley 21st Annual Global Healthcare Conference in New York on September 12, 2023.
  • Douglas Bryant, President and Chief Executive Officer, and Joseph Busky, Chief Financial Officer, will participate in a fireside chat scheduled for 2:55 p.m.
  • ET / 11:55 a.m. PT.

Fresenius Kabi and Lupagen Enter into Strategic Development and Supply Agreement to Bring Cell and Gene Therapies to the Bedside

Retrieved on: 
Thursday, August 24, 2023
Hospitals, Genetics, Fitness & Nutrition, Stem Cells, Biotechnology, Other Health, Health, General Health, Oncology, Fresenius (company), Gene, Multimedia, Kabi, Collection, Patient, Blood, Cancer, Cell, Transfusion medicine, R, Rare, Autoimmunity, Vaccine, Medical device

Fresenius Kabi and Lupagen Inc. announced today the companies have entered into a development and supply agreement for technologies designed to bring the delivery of cell and gene therapies to the bedside.

Key Points: 
  • Fresenius Kabi and Lupagen Inc. announced today the companies have entered into a development and supply agreement for technologies designed to bring the delivery of cell and gene therapies to the bedside.
  • View the full release here: https://www.businesswire.com/news/home/20230824736387/en/
    Cell and gene therapies have shown great promise for a wide array of conditions including cancers and hematologic, autoimmune, and rare diseases.
  • Under the terms of the agreement, Fresenius Kabi will provide their expertise in apheresis collection and automated cell processing equipment to advance Lupagen’s Extracorporeal Cell and Gene Therapy Delivery System, which focuses on simplifying and reducing costs for cell and gene therapy through a bedside procedure.
  • “Lupagen’s mission is to make cell and gene therapy as common and widely accessible as standard blood transfusion or dialysis procedures.